Entrada Therapeutics Inc. (TRDA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
TRDA Chart
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pediatric drug exposure provides a plausible, testable explanation; higher dosing results are expected in Q1 2027. Valuation is anchored by risk-adjusted pipeline estimates and significant cash reserves, with downside to $4–$4.60 if higher dosing fails to deliver.
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.04 per share a year ago.
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Entrada Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 273 | $2,109.62 | $1,242.15 | -$867.47 | -41.12% |
| DS Danny Salinas Cantor Fitzgerald LP | 60,000 | $368,280 | $278,400 | -$89,880 | -24.41% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 33,351 | $341,063.86 | $162,252.61 | -$178,811.25 | -52.43% |
 John H. Burbank III Passport Capital LLC | 5.07M | $84.63M | $24.68M | -$59.95M | -70.84% |
| KJD Kathryn J. Daniels Canada Pension Plan Investment Board | 17,700 | $181,956 | $77,349 | -$104,607 | -57.49% |
Entrada Therapeutics Inc. (TRDA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Entrada Therapeutics Inc. ever had a stock split?
Entrada Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dipal Doshi CEO | NASDAQ (NMS) Exchange | 29384C108 CUSIP |
| US Country | 152 Employees | - Last Dividend | - Last Split | 29 Oct 2021 IPO Date |
Overview
Entrada Therapeutics, Inc. is an innovative biotechnology company focused on the development of therapeutics for neuromuscular diseases, using its proprietary endosomal escape vehicle (EEV) technology. The company has its roots in the initial foundation as CycloPorters, Inc., before rebranding to Entrada Therapeutics, Inc. in October 2017. Since its incorporation in 2016, Entrada Therapeutics has been dedicated to leveraging its EEV platform to create a diverse portfolio of therapeutic programs. With its headquarters in Boston, Massachusetts, the company is at the forefront of biotechnological research, particularly in the area of oligonucleotide, antibody, and enzyme-based therapeutics.
Products and Services
ENTR-601-44 for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1: ENTR-601-44 represents Entrada Therapeutics' leading product candidate, currently in the preclinical trial phase. This drug is designed to target and treat neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1 by leveraging the company's endosomal escape vehicle (EEV) technology. This innovative approach aims to provide a new avenue for therapeutic intervention in diseases that currently have limited treatment options.
EEV-PMO-CAG for Myotonic Dystrophy Type 1: Another critical project under development at Entrada Therapeutics is EEV-PMO-CAG, specifically targeting myotonic dystrophy type 1. This product underscores the company's commitment to addressing the unmet medical needs in the neuromuscular disease community by exploring therapeutics that can potentially modify disease progression and improve patient outcomes.
Contact Information
